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Low–molecular weight heparin (LMWH) is used clinically to treat clotting disorders. As an animal-sourced product,
LMWH is a highly heterogeneous mixture, and its anticoagulant activity is not fully reversible by protamine. Further-
more, the reliability of the LMWH supply chain is a concern for regulatory agencies. We demonstrate the synthesis of
heparin dodecasaccharides (12-mers) at the gram scale. In vitro experiments demonstrate that the anticoagulant ac-
tivity of the 12-mers could be reversed using protamine. One of these, labeled as 12-mer-1, reduced the size of blood
clots in the mouse model of deep vein thrombosis and attenuated circulating procoagulant markers in the mouse
model of sickle cell disease. An ex vivo experiment demonstrates that the anticoagulant activity of 12-mer-1 could
be reversed by protamine. 12-mer-1 was also examined in a nonhuman primate model to determine its pharmaco-
dynamic parameters. A 7-day toxicity study in a rat model showed no toxic effects. The data suggest that a synthetic
homogeneous oligosaccharide can replace animal-sourced LMWHs.
INTRODUCTION
Low–molecular weight heparins (LMWHs) are a widely prescribed
class of anticoagulants used to prevent and treat arterial and venous
thrombosis (1). LMWH is prepared through the chemical or enzymatic
depolymerization of unfractionated porcine heparin (UFH) (2). Com-
pared to UFH, LMWHs are more subcutaneously bioavailable, have a
longer half-life, and show a decreased risk of heparin-induced throm-
bocytopenia (HIT), a life-threatening adverse effect associatedwith hep-
arin (3, 4). LMWHs can lower the risk of HIT by as much as 63%,
substantially reducing HIT-related hospital expenditures (5). However,
LMWHs cannot simply be substituted for standard unfractionated hep-
arin in cases ofHITdue to their cross-reactivitywithHIT antibodies (3).
Major hospitals and tertiary referral centers in theUnited States, Canada,
and Europe are moving toward substituting LMWHs for UFH as
prophylaxis for venous thromboembolism. The approval of generic
forms of enoxaparin by the U.S. Food and Drug Administration
(FDA) in 2010 has reduced the drug price, making LMWHs available
to broader patient populations (6). LMWHs still have limitations. For
example, LMWHs can be used in renal-impaired patients only at re-
duced doses (7), and their anticoagulant activity is only incompletely
neutralizedwith protamine, thereby increasing bleeding risk. Although
protamine can stop bleeding caused by enoxaparin in some patients, it
is not generally viewed as a reliablemethod for neutralizing enoxaparin
(8). Because LMWH is animal-sourced, the supply chain for LMWHs
is under continued threat of contamination by adulterated products.
LMWH is a complex mixture of oligosaccharide natural products,
consisting of a disaccharide repeating unit of either iduronic acid (IdoA)
or glucuronic acid (GlcA) and glucosamine (GlcN) residues, with each
residue capable of carrying sulfate groups. These oligosaccharides range
from6 to 30 residues long and display awide range of sulfation patterns.
Only a fraction of oligosaccharides in LMWH exhibit anticoagulant ac-
tivity. The structural heterogeneity in LMWHs results in batch-to-batch
differences in saccharide composition and sequence and anticoagulant
activity (6).
Heparin is prepared frommucosa harvested from porcine intestine,
requiring a long and poorly regulated supply chain. The quality and
supply of LMWHs relies on the quality of animal-derived heparin.
Batches of contaminated heparin that entered the worldwide market
in late 2007 were responsible for many deaths, making this one of the
worst incidents of a toxic drug product reaching the market in U.S.
history (9). The contaminated heparin also adversely affected the pu-
rity of LMWHs (10), revealing the fragility of the LMWH supply
chain. One form of synthetic heparin pentasaccharide, known as fon-
daparinux, is currently on the market (11). Fondaparinux is contra-
indicated for kidney-impaired patients, and its anticoagulant activity
cannot be reversed by protamine (12). Thus, it is unlikely to substitute
for enoxaparin.
We have been actively developing a method to prepare synthetic
LMWH to bypass the need for animal-sourced heparin (13). Unlike
traditional synthesis using a purely chemical approach, we rely on a
chemoenzymatic synthesis method using a variety of heparin bio-
synthetic enzymes. Chemoenzymatic synthesis is a highly efficient
method for preparing structurally heterogeneous heparin polysac-
charides (14, 15) as well as structurally homogeneous LMWH (12)
and ultra-LMWH (16). This chemoenzymatic method also allows the
design of LMWH oligosaccharide structures that display improved
pharmacological properties. An LMWH synthesized by this method
displays anticoagulant activity that is protamine-reversible, thereby
reducing bleeding risk (12). However, until now, the chemoenzymatic
synthesis could only be used to prepare a given product at the milli-
gram scale and has been an impractical approach for the replace-
ment of animal-sourced LMWHs.
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Here, we report the design of a homogeneous LMWH oligo-
saccharide that is amenable to multigram-scale chemoenzymatic syn-
thesis. The synthesized LMWH oligosaccharide was evaluated in
disease-related mouse models, used for pharmacodynamic analysis in
nonhuman primates, and examined by toxicological analysis in rats.
The results suggest a cost-effective scheme for the preparation of a syn-
thetic oligosaccharide as a substitution candidate for animal-sourced
LMWHs.
RESULTS
Identification of synthetic LMWH constructs for
scaled-up preparation
Wesynthesized twododecasaccharides, 12-mer-1 and12-mer-2 (Fig. 1A),
using a chemoenzymatic method. The synthesis was initiated from a
commercially available acceptor, p-nitrophenyl glucuronide (GlcA-
pNP), using uridine diphosphate (UDP)–sugar donors, a glycosyltrans-
ferase, four or five different sulfotransferases, and an epimerase (Fig. 1B).
The synthesis of 12-mer-1 was completed in 22 steps with an overall
yield of 10.3%, and the synthesis of 12-mer-2 was completed in 23 steps
with an overall yield of 8.2% (Fig. 1B and fig. S1). 12-mer-1 has one 3-O-
sulfated glucosamine (GlcNS3S6S) residue that is located at residue
C, whereas 12-mer-2 has two GlcNS3S6S residues that are located at
residues C and G (Fig. 1A). These are different from our previously re-
ported dodecasaccharide LMWH constructs (12), because their non-
reducing end contains an N-sulfo glucosamine (GlcNS) residue in
place of an N-acetyl glucosamine (GlcNAc) residue. This modification,
suggested by analyzing the crystal structures of the 6-O-sulfotransferase
(6-OST) (17), increased the reactivity of the substrate, making complete
6-O-sulfation considerably easier (reaction f, Fig. 1B). Six 6-O-sulfo
groups were installed into each dodecasaccharide in a single reaction
step. Complete 6-O-sulfation reaction avoided the necessity of purifying
the product from a mixture of partial 6-O-sulfated 12-mers, increasing
product purity and yield. A total of 1300mg of 12-mer-1 and 110mg of
12-mer-2 were synthesized (Fig. 1 and fig. S1).
Improvements in the enzymeandcofactorproductionalso contributed
to the success of our chemoenzymatic synthesis. Both C5-epimerase
(C5-epi) and 2-O-sulfotransferase (2-OST)were expressed in insect cells
using the baculovirus expression system (18). The activity levels of recom-
binant C5-epi and 2-OST from insect cells were 225- and 75-fold greater,
respectively, than the same enzymes expressed in Escherichia coli. The
cost for Sf9 cell-conditioned medium was ~$60/liter, and the cost
for E. coli culture was ~$3/liter. The excellent expression of C5-epi and
2-OST offsets the higher costs of culturing insect cells. The syntheses
Fig. 1. Chemical structures and synthetic scheme of synthetic LMWHs, 12-mer-1 and 12-mer-2. (A) Chemical structures of 12-mer-1 and 12-mer-2. The name of each
residue (A to L) is indicated at the top of the panel. The differences between two 12-mers are the number of 3-O-sulfo groups present: one in 12-mer-1 in residue C and
two in 12-mer-2 in residues C and G (highlighted). pNP represents p-nitrophenyl group. (B) Synthetic schemes for 12-mer-1 and 12-mer-2 using shorthand symbols.
Each reaction step uses different enzymes and chemicals: a, PmHS2 (heparosan synthase 2 from Pasteurella multocida) and UDP-GlcNTFA; b, PmHS2 and UDP-GlcA; c,
LiOH; d, N-sulfotransferase (NST) and 3′-phosphoadenosine 5′-phosphosulfate (PAPS); e, C5-epimerase (C5-epi), 2-O-sulfotransferase (2-OST), and PAPS; f, 6-OST-1, 6-OST-3, and
PAPS; g, 3-O-sulfotransferase isoform 1 (3-OST-1) and PAPS; h, 3-OST-5 and PAPS. Full synthetic schemes using chemical structures are shown in fig. S1.
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of cofactors, including UDP-trifluoroacetyl glucosamine (GlcNTFA),
UDP-GlcA, and PAPS, were accomplished using enzymes expressed
in E. coli under a whole-cell format. This format permitted us to rou-
tinely carry out 20- to 50-g scale production to support the 12-mer
syntheses, because it eliminated the required purifications of the en-
zymes used in cofactor synthesis.
The 12-mers were analyzed for purity by high-resolution anion-
exchange high-performance liquid chromatography (HPLC). Structural
analysis used high-resolution mass spectrometry (MS) and one-
dimensional (1D) and 2Dnuclearmagnetic resonance (NMR) analyses.
Both 12-mer-1 and 12-mer-2 showed a major single symmetric peak
on theHPLC analysis, suggesting that the purities for both compounds
were >98% (fig. S2). High-resolution MS analyses of 12-mer-1 and
12-mer-2 afforded observed masses of 3520.8280 and 3600.7848, re-
spectively. These measured values were consistent with the calculated
exact mass values of 3520.8928 (for 12-mer-1) and 3600.8550 (for
12-mer-2) (fig. S3). 1D and 2D NMR analyses confirmed the purity
of 12-mer-1, and spectral assignment definitively provided its struc-
ture (figs. S4 to S8). Similar NMR analysis of 12-mer-2 confirmed
its purity and provided many structural details (figs. S9 to S13), but
the presence of its second 3-O-sulfo group required additional analy-
ses. MS-based sequence analysis of 12-mer-2 was performed to pre-
cisely position its 3-O-sulfo groups (figs. S14 to S16) (19). Analysis of
the products from 12-mer-2 formed by digestion with heparin lyases I
and II allowed us to confirm the presence of a 3-O-sulfo group on res-
idue G. A comparison of the NMR spectra of 12-mer-1 and 12-mer-2
(figs. S17 to S19) further supported their structural assignment.
In vitro and in vivo evaluation of the anticoagulant activities
of the 12-mer oligosaccharides
The in vitro anticoagulant activity and its protamine neutralizationwere
measured in comparison to UFH and to two other FDA-approved hep-
arin drugs, fondaparinux and enoxaparin (Fig. 2, A to C). 12-mer-1 and
12-mer-2 displayed potent anti–factor Xa (FXa) activity with a median
inhibitory concentration (IC50) of 57 and 67 ng/ml, respectively (Fig.
2A). Similar IC50 values (21 and 35 ng/ml) for the anti-FXa activity were
reported for two different 12-mers published previously (12). The anti–
factor IIa (FIIa) activity of UFH was determined at the IC50 value of
86 ng/ml. However, neither 12-mer-1 nor 12-mer-2 displayed any in-
hibition of the activity of FIIa at the concentration of 50,000 ng/ml,
making both oligosaccharides specific FXa inhibitors. The anti-FXa ac-
tivities of 12-mer-1 and 12-mer-2 were reversible through the addition
of protamine, and their sensitivity to protamine neutralization was
comparable to that measured for UFH (Fig. 2B). Fondaparinux was
completely insensitive to protamine neutralization, and the anti-FXa ac-
tivity of enoxaparin was only partially neutralized using protamine (Fig.
2B). Subsequent biological studies focused on 12-mer-1 because it was
easier to synthesize. In ex vivo experiments, administration of 12-mer-1
to a mouse also inhibited FXa activity, and its anti-FXa effect was
diminished over 6 to 8 hours as the drugwas cleared (fig. S20), confirm-
ing the anticoagulant activity of 12-mer-1.
Protamine neutralization of 12-mer-1 was also determined using an
ex vivo mouse model. As a positive control for this model, the anti-FXa
activity of UFH was effectively neutralized by protamine (Fig. 2C).
Consistent with the results demonstrated in the in vitro analysis of
Fig. 2. In vitro, ex vivo, and in vivoanalysis of the anticoagulant activity of 12-mers. (A) FXa inhibition curves of 12-mers and UFH in vitro. Data are means ± SD (n = 4).
(B) Neutralization of FXa activity of 12-mers by protamine in vitro. In addition to 12-mers, UFH was included as a positive control, and fondaparinux and enoxaparin
were included as negative controls. Data are means ± SD (n = 4). (C) Reversibility of anti-FXa activity by protamine in an ex vivo experiment. The statistical significance
for the comparison of each sample with and without protamine is indicated (P < 0.001). (D) Reduction of clot weight in a venous thrombosis mouse model treated with
PBS, enoxaparin, and 12-mer-1. (E) Plasma concentration of thrombin anti-thrombin (TAT) complexes and (F) FXa activity in control (AA) and sickle BERK (SS) mice
injected with PBS or 12-mer-1 (2 mg/kg) subcutaneously every 8 hours for 7 days (n = 8 to 13). Blood was collected 2 hours after the last injection. Data are means ± SD.
*P < 0.05, ***P < 0.001, ****P < 0.0001. n.s., not significant.
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12-mer-1, its anti-FXa activity was effectively reversed by protamine,
whereas the activity of enoxaparin was only partially reversed (Fig. 2C).
Protamine neutralization data indicate that the extent of FXa activity
forUFH-treatedmicewas higher than that for 12-mer-1–treatedmice,
suggesting that some residual anti-FXa activity from 12-mer-1 still
remained (Fig. 2C).The residual anti-FXa activity from12-mer-1 could
probably be neutralized using a higher concentration of protamine.
Evaluation of 12-mer-1 in disease models
A common indication for LMWH is for thromboprophylaxis in pa-
tients with a high risk of venous thromboembolism. Thus, we assessed
the effect of 12-mer-1 on thrombosis in a mouse model of venous
thrombosis induced by stenosis of the inferior vena cava (20, 21). As
expected, 24 hours after stenosis, 12-mer-1 significantly reduced clot
weight (by ~60%, P < 0.05) compared to mice treated with phosphate-
buffered saline (PBS) (Fig. 2D). Mice treated with enoxaparin showed a
similar reduction of clot weight and incidence of thrombosis (Fig. 2D).
These data demonstrate that 12-mer-1 reduces the formation of venous
thrombosis. Notably, the dose of 12-mer-1 used in this experiment
(1.5 mg/kg) was only one-fifth of the required dose of enoxaparin
(7.5 mg/kg), showing that 12-mer-1 had considerably higher anti-
thrombotic potency.One reason for this higherpotency is that enoxaparin
is composed of amixture of active and inactive oligosaccharides, whereas
12-mer-1 is a homogeneous active oligosaccharide.
Next, we evaluated the anticoagulant properties of 12-mer-1 in a
mouse model of sickle cell disease (SCD) (22). Chronic activation of
coagulation is observed both in sickle cell patients and in the mouse
model of the disease (23–25). SCD is also
associatedwithmultiple end-organ dam-
age, including kidney (26, 27). Sickle cell
mice and control mice received sub-
cutaneous injections of saline or 12-mer-1
(2.0 mg/kg) every 8 hours for 7 days.
12-mer-1 significantly attenuated the ac-
tivation of coagulation in sickle cell mice
(P < 0.05), as demonstrated by the reduc-
tion of plasma thrombin/antithrombin
(TAT) complexes (Fig. 2E). At the end
of the experiment, the FXa activity in the
plasma of sickle cell mice was higher than
in the plasma of control mice (Fig. 2F),
suggesting that the accompanying kidney
pathology in the sickle cell mice enhances,
rather than reduces, the clearance of 12-
mer-1. This result could be explained by
the well-documented increase of renal
blood flow and glomerular filtration rate
observed in both sickle cell patients and
mouse models of the disease (28, 29).
Because LMWHs are cleared through
the kidney, the dosing regimen must be
reduced in renal-impaired patients.
Therefore, we investigated the clearance
of 12-mer-1 in mice with severe kidney
failure caused by the removal of one kid-
ney and by subjecting the remaining kid-
ney to ischemia/reperfusion (I/R) injury
(Fig. 3A). We confirmed that these ex-
perimental conditions caused acute kid-
ney failure, demonstrated by increased plasma concentrations of
creatinine at the end of the reperfusion period (2.19 ± 0.11mg/dl versus
0.15 ± 0.03 mg/dl, respectively; P < 0.0001) in mice that had been op-
erated on when compared to control mice undergoing a sham operation.
UFH is considered to be safe for kidney-impaired patients (30), and thus,
kidney failure does not alter the clearance of UFH, as demonstrated by
similar FXa activity observed in the plasma of mice with kidney failure
and control mice undergoing a sham operation (Fig. 3B). In contrast,
compared to the sham-operated mice, the clearance of both high-dose
(1.5 mg/kg) and low-dose (0.3 mg/kg) 12-mer-1 was significantly im-
paired in mice with kidney failure (P < 0.05), as demonstrated by a
reduction of plasma FXa activity 2 hours after injection of 12-mer-1
(Fig. 3B). The impairment of 12-mer-1 clearance depends on the se-
verity of the kidney injury. Reducing the severity of kidney injury by
shortening the ischemic period increased plasma FXa activity in injured
mice injectedwith 12-mer-1 at a dose of 0.3mg/kg (Fig. 3C). These data
demonstrate the impairment of 12-mer-1 clearance in mice suffering
from kidney failure.
Pharmacodynamic analysis of 12-mer-1 in a nonhuman
primate model
The 12-mer-1 oligosaccharide was administered to theMacacamulatta
primate model either intravenously or subcutaneously at a dose of
250 mg/kg. The plasma concentration of 12-mer-1 over time after ad-
ministration was assessed by anti-FXa assay (fig. S21). On intravenous
administration, the drug immediately distributed through the circulato-
ry system. The earliest data point that was captured was 30min after the
Fig. 3. Clearance of 12-mer-1 in kidney I/R injury model in C57BL/6J mice. (A) Kidney I/R experimental scheme.
(B) Plasma activity of FXa in mice subjected to kidney I/R injury (30 min of ischemia time followed by 24 hours of
reperfusion) and injected subcutaneously with UFH (n = 6; 3 mg/kg), 12-mer-1 (n = 6; 1.5 mg/kg), or 12-mer-2 (n = 6;
0.3 mg/kg). (C) Plasma activity of FXa in sham-operated mice and mice subjected to different ischemia periods (20,
25, and 30 min). Mice received subcutaneous injection of PBS or 12-mer-1 (0.3 mg/kg) after 24 hours of reperfusion,
and plasma was collected 2 hours later (n = 6 for each group). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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injection (Fig. 4A). From the drug elimination profile, the calculated
half-life of 12-mer-1 was 67 min. On subcutaneous administration,
the drug reached a maximum plasma concentration 2 hours after
injection (Fig. 4B). The calculated half-life for 12-mers administered
through the subcutaneous route was 2.9 hours. A higher dose of
12-mer-1 (500 mg/kg) was next administered by intravenous and sub-
cutaneous routes (fig. S22). At this higher dose, the half-lives for intra-
venous and subcutaneous routes were 72 min and 3.4 hours,
respectively. The data demonstrate that whereas the route of adminis-
tration affects the clearance rate, the dose does not.
Toxicology studies of 12-mer-1
Toxicology studies on 12-mer-1were per-
formed in Sprague-Dawley rats. Here, a
single dose of 3600 mg/kg per day, 7.2-
to 14.4-fold higher than the dose used in
the nonhuman primate model, was intra-
venously given to rats for seven consecu-
tive days. Blood samples were drawn for
serum chemistry analysis at day 8, and
all organs were harvested to measure the
organ and body weights (Table 1). All ser-
umchemistry parameters in the 12-mer-1–
treated animals were essentially identical
to those from the control group. A de-
crease in total white blood cells was ob-
served in the treated group; however,
these values were within the laboratory’s
historical control data range and, thus,
Fig. 4. Clearanceof 12-mer-1 fromanonhumanprimatemodel.M. mulattamonkeys were treated with 12-mer-1 at
a dose of 250 mg/kg either intravenously (IV) (A) or subcutaneously (SC) (B). Blood samples were collected before
dosing (at t = 0 hour) and at 30, 60, and 120 min after dosing (for IV group) or at 1, 2, 4, and 6 hours after dosing (for
SC group). The plasma concentration of 12-mer-1 was determined by measuring the activity of FXa, which was
converted into the concentration of 12-mer-1 by a standard curve, as shown in fig. S21. Data are average ± range
(n = 2).
Table 1. Toxicological results and organ weights.
Parameters Control (n = 5) 3600 mg/kg (n = 5) Historical control values*
White blood cells (×103/ml) 9.9 ± 1.1 7.8 ± 1.0 9.6 ± 3.0
Red blood cells (×106/ml) 8.3 ± 0.2 8.1 ± 0.3 8.5 ± 0.6
Hemoglobin (g/dl) 15.1 ± 0.4 14.8 ± 0.3 15.9 ± 0.9
Blood urea nitrogen (mg/dl) 18.0 ± 2.2 17.8 ± 2.4 18 ± 3.2
Creatinine (mg/dl) 0.40 ± 0.01 0.42 ± 0.03 0.46 ± 0.12
Albumin (g/dl) 3.54 ± 0.06 3.62 ± 0.08 3.4 ± 0.17
Total bilirubin (mg/dl) 0.11 ± 0.01 0.10 ± 0.01 0.12 ± 0.024
Alanine aminotransferase (U/liter) 43.6 ± 8.1 38.6 ± 2.4 46 ± 15.3
Total protein (g/dl) 6.18 ± 0.16 6.28 ± 0.11 6.2 ± 0.41
Body weight (g)† 268.4 ± 4.2 271.4 ± 5.9
Organ–to–body weight ratio†
Brain 0.69 ± 0.04 0.71 ± 0.02
Adrenal glands 0.026 ± 0.014 0.020 ± 0.004
Heart 0.41 ± 0.04 0.41 ± 0.02
Kidneys 0.73 ± 0.05 0.70 ± 0.04
Liver 3.04 ± 0.09 3.04 ± 0.11
Spleen 0.25 ± 0.01 0.25 ± 0.02
Testes 1.36 ± 0.04 1.29 ± 0.06
Thyroid/parathyroid 0.0062 ± 0.0011 0.0058 ± 0.0011
*The historical control value was obtained from the analysis of ~1750 individual normal rats. †Body weight and organ weight were measured on day 8.
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are not considered toxicologically adverse. The organ–to–body weight
ratios among treated and control groups were indistinguishable. Two
additional dose regimens for 12-mer-1, 400 and 1200 mg/kg per day,
were also examined in these studies (table S1). Together, the data con-
firm that 12-mer-1 is well tolerated, dampening concern about the
potential toxicity of the p-nitrophenyl group present at the reducing
end of 12-mer-1 (12, 31).
DISCUSSION
The introduction of LMWHs in the 1990s afforded a relatively safe class
of subcutaneously bioavailable anticoagulant drugs. LMWHs remain as
the drug class of choice for cancer patients (32) and pregnant women
(33) despite the emergence of newer nonheparin oral anticoagulant
drugs in recent years. However, the reliance on a single animal species
coming predominately from one country for the LMWH supply chain
and the burden imposed on regulatory agencies for ensuring the safety
of structurally heterogeneous LMWH products remain serious
concerns. Despite extensive efforts from the FDA and U.S. Pharmaco-
peia to improve the purity analysis after the heparin crisis in 2007, the
animal-sourced heparin is still not 100% risk-free because of the lack of
“unequivocal and specific analytical techniques” (9). The U.S. Congres-
sional Committee on Energy and Commerce has also raised concerns
over the safety of the heparin supply chain in a letter to the FDA in 2016
(https://energycommerce.house.gov/news-center/press-releases/
committee-leaders-express-continued-concern-fda-s-califf-about).
These actions from the regulatory agency and the U.S. Congress dem-
onstrate that the safety of the supply of heparin andLMWHis of interest.
A major challenge for the penetration of the heparin market by ho-
mogeneous heparin products is the ability to cost-effectively synthesize
such compounds. There are concerns over the scalability of chemoen-
zymatic synthesis of LMWH. Here, we report the gram-scale synthesis
of a homogeneous dodecasaccharide and demonstrate it to be a candi-
date to replace LMWHs in thromboprophylaxis. Our synthesis was
accomplished using standard equipment found in an academic labora-
tory by carefully designing the structure of the target oligosaccharide,
improving the expression of heparin biosynthetic enzymes and cofactor
production. The scale of the synthesis can be increased in a pilot plant or
an industrial facility with large-scale fermentation and liquid-handling
equipment. There is no doubt that substantial optimization and im-
provement for the processes of the expression of enzymes and product
purification will be required to be suitable for industrial-scale synthesis.
One notable successful example that translates a laboratory synthesis to
industrial production is the synthesis of fondaparinux, which involves
~50 synthetic steps. The first synthesis was only completed at the
milligram scale (34, 35), but it is now synthesized at the kilogram scale
(36). The product occupies a sizeable share of heparin market.
Enoxaparin has a half-life of 5 to 6 hours when subcutaneously
administered in the same nonhuman primatemodel used in the current
study (37). Similar elimination rates observed for 12-mer-1 and enox-
aparin offer an insight for designing the dose regimen for future human
clinical trials. Enoxaparin is administered either twice a day or once a
day as thromboprophylaxis in the clinic. We anticipate that 12-mer-1
could be used in a similar regimen, although at lower doses than enox-
aparin, because 12-mer-1 is a more potent compound.
Previously, we reported that dodecasaccharides with similar struc-
tures bound to stabilin-2 receptors on the liver sinusoidal endothelium,
suggesting that a 35S-labeled dodecasaccharide at a low dose is cleared
by the liver rather than kidney (12). The current study found that the
clearance of 12-mer-1 is impaired in the mice with I/R-injured kidneys,
a model for kidney failure. These data suggest that 12-mer-1 may ac-
cumulate in patients with severe kidney impairment, increasing the
risk for bleeding. Fortunately, because 12-mer-1 is a structurally ho-
mogeneous compound, it would allow a dose adjustment for kidney
failure patients.
In contrast to the reduced clearance observed in mice with severe
kidney failure, clearance of 12-mer-1 was modestly increased in SCD
mice. This is likely due to an increased renal blood flow and glomerular
filtration rate described in children and young adults with SCD as well
as sickle cell mice (28, 29). Renal hyperfiltration in SCD increases
proximal tubular transport, which is the dominant mechanism respon-
sible for renal excretion of LMWH (38) and, most likely, excretion of
12-mer-1. Renal filtration in SCD normalizes with age or after the de-
velopment of nephropathy and is reduced below normal as nephropa-
thy progresses into overt renal failure.
The overall risk of major bleeding associated with LMWH is 1 to 4%
(39). The reversibility of 12-mer-1 anticoagulant activity using prot-
amine should improve the safety of anticoagulant therapy. Protamine,
a polycationic polypeptide, is used to neutralize UFH; however, adverse
effects have been reported (40). Newer reversing agents have recently
emerged (41, 42). For instance, an engineered FXa-like protein, known
as andexanet, neutralizes the effects of LMWHaswell as oral direct FXa
inhibitors such as rivaroxaban and apixaban (42). Results from clinical
trials indicate that andexanet is well tolerated by patients and effectively
reverses bleeding effects caused by rivaroxaban or apixaban with 81%
(26 of 32 patients) and 65% (20 of 31 patients) efficacy, respectively
(43, 44). However, only one in four patients (25%) treated with enox-
aparin responded effectively to andexanet treatment (44). One plausible
explanation is that enoxaparin displays both anti-FXa and anti-FIIa ac-
tivity, whereas andexanet is designed to be a specific agent for reversing
FXa-specific inhibitors. If this is the case, then we anticipate that andex-
anet would be more effective in neutralizing the specific anti-FXa activ-
ity of 12-mer-1.
The introduction of heparin and LMWHs has advanced modern
medicine, as demonstrated by their widespread application in surgical
procedures and in kidney dialysis. A cost-effective method to prepare
synthetic LMWH should improve the safety and reliability of these
life-saving drugs. The next generation of safer, reliable, and affordable
synthetic LMWH drugs should greatly benefit patients.
MATERIALS AND METHODS
Study design
This study was designed to synthesize homogeneous 12-mers with the
goal of replacing animal-sourced LMWHs. We demonstrate the
chemoenzymatic synthesis of two 12-mers that can substitute for
LMWHs. The synthesis of 12-mers was repeated more than two times.
The structures were confirmed using both NMR and high-resolution
MS. Biological evaluation was conducted to evaluate the anticoagulant
activity of the synthesized 12-mers. FXa activity was used as a surrogate
to assess the anticoagulant activity. The reversal effect of protamine on
the anticoagulant activity of 12-mers was also assessed by FXa assay. The
in vitro anti-FXa activity measurement and protamine reversibility ex-
periment were repeated three times. Themurine studies were performed
with blinding; the rat and nonhuman primate studies were not blinded.
Animals were randomly assigned to the control or treated groups. The
number of animals in each experiment was determined on the basis
of previous experiences. The in vivo anti-FXa activity and protamine
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reversibility effect were performed in mice with four animals in each
group, and no outliers were found. Amousemodel of venous thrombosis
induced by stenosis of the inferior vena cava was used to determine the
antithrombotic effects of 12-mer-1with eight animals in each cohort. This
experiment was repeated twice. The pharmacodynamic study inmonkeys
was completed in two doses with two animals per group. A 7-day toxicity
study was completed in a rat model with five rats in each cohort. A total
of three doses were administered to rats to determine toxic effects, but
none were observed. A detailed description ofMaterials andMethods is
provided below and is included in the Supplementary Materials.
Chemoenzymatic synthesis of 12-mers
The synthesis of 12-mer-1 and 12-mer-2 was completed according to
the chemoenzymatic method published previously (12, 45). Briefly,
PmHS2 from P. multocida was used in conjunction with UDP-sugars
to elongate the monosaccharide, GlcA-pNP, to appropriate-sized back-
bones. The backbone was then subjected to modification with NST,
C5-epi, 2-OST, 6-OST, 3-OST-1, and 3-OST-5. There were seven ma-
jor steps involved in the overall synthesis, including step a (elongation
step to add GlcNTFA), step b (elongation step to add GlcA), step c
(detrifluoroacetylation), step d (N-sulfation step), step e (2-O-sulfation/
epimerization), step f (6-O-sulfation step), step g (3-O-sulfation by
3-OST-1), and step h (3-O-sulfation by 3-OST-5) (Fig. 1B and fig. S1).
These steps were repeated to prepare the final 12-mer products. The
products were purified by anion-exchange chromatography using a Q
Sepharose column.The structures of the products were proven byNMR
and high-resolution MS.
Removal of endotoxin from 12-mer-1
12-mer-1 (450 mg) was dissolved in 4 ml of endotoxin-free water and
then filtered through a 50-ml centrifugal filter unit (Amicon Ultra-15,
Ultracel-100k; Merck Millipore) at 4000 rpm for 10 min. The process
was repeated four times by refilling the sample chamber with 3 ml of
water each time. The filtered solution was collected and dried. The level
of endotoxinwasmeasured using the Limulus Amebocyte Lysate (LAL)
Kit (Associates of Cape Cod Inc.). Briefly, the LAL test was performed
by adding 0.1 ml of reconstituted Pyrotell (sensitivity, 0.03 endotoxin
units/ml) to 0.1 ml of the test sample, 12-mer-1, at various concentra-
tions (96, 48, 24,12, 6, 3, and 1.5 mg/ml) in a 10 mm × 75 mm depyr-
ogenated glass reaction tube (Associates of CapeCod Inc.). The reaction
solution was mixed thoroughly and placed immediately in a dry block
incubator at 37°C for 60 ± 2min. At the end of the incubation, the tube
was removed and inverted 180°. If a gel clot was formed and remained
intact in the bottom of the tube, the test was considered positive for en-
dotoxin presence, and the concentration of endotoxin was determined
to be greater than or equal to the sensitivity of Pyrotell.
Determination of the in vitro and ex vivo anti-FXa and
anti-FIIa activity
Assays were based on a previously published method (46, 47). Briefly,
human FXa (Enzyme Research Laboratories) was diluted to 50 U/ml
with PBS. The chromogenic substrate S-2765 (Diapharma) was diluted
to 1mg/ml in water. UFH (U.S. Pharmacopeia), enoxaparin (from local
pharmacy), fondaparinux, and 12-mers were dissolved in PBS at vari-
ous concentrations (3 to 600 mg/ml). The reaction mixture, which con-
sisted of 20 ml of human plasma (Sigma-Aldrich) and 45 ml of the
solution containing the sample at different concentrations, was incu-
bated at room temperature for 5 min. FXa (100 ml) was then added.
After incubating the reaction at room temperature for 4 min, we added
30 ml of the S-2765 substrate. The absorbance of the reaction mixture
wasmeasured at 405 nmcontinuously for 5min. The absorbance values
were plotted against the reaction time. The initial reaction rates as a
function of concentration were used to calculate the IC50 values.
Anti-FIIa activity assays were based on a previously published
method (48). Briefly, thrombin from bovine plasma (Sigma-Aldrich)
was diluted to 10 U/ml in PBS with bovine serum albumin (1 mg/
ml). The chromogenic substrate S-2238 (Diapharma) was made up at
1mg/ml in PBS.UFH (U.S. Pharmacopeia) and 12-mers were dissolved
in PBS at various concentrations (0.1 to 5 ng/ml and 10 ng/ml to 1 mg/ml).
The reactionmixture, which consisted of 60 ml of antithrombin (35 mg/ml,
Cutter Biologics) and 10 ml of the solution containing the sample, was
incubated at room temperature for 2min. Thrombin (100 ml) was then
added. After incubating at room temperature for 4 min, 30 ml of the
S-2238 substrate was added. The absorbance of the reaction mixture
wasmeasured at 405 nmcontinuously for 5min. The absorbance values
were plotted against the reaction time. The initial reaction rates as a
function of concentration were used to calculate the IC50 values.
Neutralization of synthetic 12-mers by protamine
The procedures followed a previous publication (49). The 12-mers and
protamine chloride (Sigma-Aldrich) were dissolved in PBS. The con-
centrations of the 12-mers were different because each construct has
a different IC50 value for the anti-FXa activity. The reaction mixture
consisted of 20 ml of human plasma (Sigma-Aldrich); 45 ml of the stock
solutions of enoxaparin, UFH, fondaparinux, and 12-mers (the concen-
tration was 25× IC50); and 20 ml of protamine at various concentrations
(from0 to 90 mg/ml), andwas incubated at room temperature for 5min.
The mixture (85 ml) was then subjected to anti-FXa activity measure-
ment as described above.
Neutralization of 12-mer-1 by protamine in mice
The study was performed on 8-week-old male C57BL/6J mice (The
Jackson Laboratory) (n = 4 per group). The mouse experiments were
approved by the University of North Carolina (UNC) Animal Care
and Use Committees and complied with National Institutes of Health
guidelines. Under isoflurane anesthesia, mice were subcutaneously treated
with PBS,UFH (3mg/kg), enoxaparin (3mg/kg), or 12-mer-1 (0.6mg/kg)
30min before protamine administration. Protamine (15mg/kg) or PBS
was administered intravenously through retro-orbital plexus injection,
and 5 min later, blood samples were drawn from the inferior vena cava
into syringes preloaded with 3.2% solution of sodium citrate (blood/
citrate solution ratio was 9:1). To obtain mouse plasma, blood samples
were centrifuged at 4000g for 15 min at 4°C. Mouse plasma was then
used to determine anti-FXa activity. Ex vivo analysis of anti-FXa activity
was done similar to the in vitro study described above. The anti-FXa
activity in the mouse plasma from the PBS-injected mice was defined
as 100%. Statistical analysis formultiple comparisons was performed by
two-way analysis of variance (ANOVA) with Bonferroni’s post hoc test
(GraphPad Prism Software).
Evaluation of in vivo thrombosis in a murine vena cava
stenosis model
Amurine model of thrombosis (also known as St. ThomasModel) (20)
was used to evaluate the anticoagulant potential of the 12-mers. Briefly,
adult male Balb/c mice (The Jackson Laboratory) were anesthetized
with an intraperitoneal ketamine (100 mg/kg)/xylazine (15 mg/kg)
cocktail, and the infrarenal vena cava was exposed. Major side branches
were ligated with 5-0 silk. A stenosis was created in the vena cava just
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caudal to the left renal vein by using a 5-0 nylon spacer, placing a 5-0
ligature around both the vena cava and the spacer, and then removing
the spacer after tying the ligature. A mini bulldog clamp (#18053-28,
Fine Science Tools) was then applied for 15 s onto the vena cava caudal
to the ligation point at two different locations. The woundwas closed in
two layers. Subcutaneous injections of the 12-mers (1.5 mg/kg), enox-
aparin (7.5 mg/kg), or PBS control were given at 30 min, 5 hours, and
10 hours after the creation of the stenosis. Mice were reanesthetized at
24 hours, and the clots were harvested andweighed. Statistical analysis
for multiple comparisons was performed by one-way ANOVA with
Bonferroni’s post hoc test (GraphPad Prism Software).
Mouse model of SCD
BERK mice on a mixed genetic background (FVB/N, 129, DBA/2,
C57BL/6, and Black Swiss) were used (22). BERKmice have a transgene
containing normal human a-, g-, d-globins; sickle b-globin; and tar-
geted deletions of murine a- and b-globins (a−/−, b−/−, Tg). We gener-
ated these mice by intercrossing a−/−, b−/−, Tg males with a−/−, b+/−, Tg
females. As a control, we used wild-type (WT) mice on a similar mixed
genetic background that have no human transgenes (a+/+, b+/+). Four-
to 6-month-old mice were used. All mouse experiments were approved
by the UNCAnimal Care and Use Committees and complied with Na-
tional Institutes of Health guidelines.
The anticoagulant effect of 12-mer-1 in SCD model
Four-month-old BERK andWTmice (both male and female) received
subcutaneous injection of PBS or 12-mer-1 (2 mg/kg) every 8 hours for
7 days. Blood was collected from the inferior vena cava 2 hours after the
last injection to quantify plasma FXa activity and TAT.
Determination of TAT
Mouse plasma concentration of TAT was analyzed using commercial
enzyme-linked immunosorbent assay following the manufacturer’s in-
structions (Siemens Healthcare Diagnostics).
Mouse model of kidney failure induced by I/R injury
Severe kidney failure was induced in 2- to 3-month-old C57BL/6 male
mice (The JacksonLaboratory) by subjecting them to aunilateral I/Rwith
simultaneous contralateral nephrectomy (50). Briefly, mice were anes-
thetized with a mixture of ketamine (80 mg/kg)/xylazine (16 mg/kg).
Mice underwent a midline laparotomy followed by the removal of
one kidney.Unilateral ischemiawas induced by clamping the renal artery
on the other kidney at the desired ischemia time using a vascular clip. At
the end of ischemia, the clip was removed and kidney reperfusion was
visually confirmed as return of blush color, after which the abdomen
was closed with sutures. Sham-operated mice were only subjected to
laparotomy.After 24 hours of reperfusion,micewere subjected to sub-
cutaneous administration of PBS or anticoagulant agents. Two hours
after treatment, blood was collected from the inferior vena cava into
3.8% solution of sodium citrate (9:1, v/v). All mouse experiments were
approved by theUNCAnimal Care andUse Committees and complied
with National Institutes of Health guidelines.
The anticoagulant effect of 12-mer-1 in kidney I/R
injury model
In one study, mice with contralateral nephrectomy were subjected to
30 min of ischemia on the other kidney. After 24 hours of kidney re-
perfusion,mice were subcutaneously treatedwithUFH (n= 6, 3mg/kg)
and two different doses of 12-mer-1: 1.5 mg/kg (n = 6) and 0.3mg/kg
(n = 6). Two hours after treatment, bloodwas collected to obtainmouse
plasma to determine FXa activity. In another study, mice with contra-
lateral nephrectomy were subjected to various ischemia times (20, 25,
and 30 min) on the other kidney to modulate the severity of the kidney
injury. After 24 hours of kidney reperfusion, mice were subcutaneously
treated with 12-mer-2 (0.3 mg/kg; n = 6 for each group). Two hours
after injection, bloodwas collected to obtainmouse plasma to determine
FXa activity.
Pharmacodynamic analysis in nonhuman primates
The detailed procedures were described previously (37). Briefly, non-
human primates (M.mulatta) were anesthetized with an intramuscular
injection of ketamine (Ketaset, FortDodgeAnimalHealth) and xylazine
(AnaSed injection, Lloyd Laboratories). Upon anesthesia, the primates
were weighed and a baseline blood sample was collected by saphenous
vein puncture. A site on the abdomen was shaved and cleansed by al-
ternate wipingwith betadine and ethanol before subcutaneous admin-
istration of endotoxin-free 12-mer-1 at a dose of 250 or 500 mg/kg
using a tuberculin syringe attached to a 21-gauge needle. Intravenous
administration of 12-mer-1 at a dose of 250 or 500 mg/kg using a but-
terfly (21-gauge) needle placed in the contralateral saphenous veinwas
also performed. For both the subcutaneous and intravenous studies,
working concentrations of 2.5 and 5mg/mlweremade in sterile saline.
Blood samples were collected at 1, 2, 4, and 6 hours after subcutaneous
administration or at 0.5, 1, and 2 hours after intravenous administra-
tion. All blood samples were centrifugedwithin 15min of collection to
make platelet-poor plasma. The plasma was stored at −70°C until
analysis. Plasma samples were subjected to anti-FXa activity analysis
using the chromogenic substrate method.
Toxicology studies
The studies were carried out by Calvert Labs following standard
protocols for acute toxicity testing (51). Endotoxin-free 12-mer-1
(400 mg) was prepared as dosing solutions in 0.9% NaCl for injection
(saline solution). Experimentally naïve Sprague-Dawley male rats were
about 9 to 11weeks old at the start of dosing phase. The animals’weight
range at the start of the repeat-dose phase was 249 to 274 g. Separate
groups of five male rats were given 12-mer-1 at dose levels of 0, 400,
1200, and 3600 mg/kg per dose by intravenous bolus injection via the
lateral tail vein for seven consecutive days. Rats were observed daily
for clinical signs before dosing and 1 to 2 hours after dose administra-
tion. Animals were observed for clinical signs until scheduled necropsy
on day 8. There were no early deaths and no adverse effects with the
exception of red staining around the left eye on days 2 and 3 for one
male in the 1200 mg/kg per dose group. No clinical signs of toxicity were
observed over the 7-day dosing period in any animal.
Body weights were recorded before drug administration on days 1,
4, and 7. Food consumption was recorded on days 1 and 7 to calculate
food consumption for the dosing period. On day 8, five rats per group
were euthanized by CO2 asphyxiation. At scheduled necropsy, whole-
blood samples were collected for evaluation of specific hematology
and serum chemistry parameters. Gross pathologic findings were re-
corded, selected organs were weighed, and selected tissues were har-
vested and preserved. No abnormalities were observed during the
course of the study.
Statistical analysis
All statistical analyses were performed using GraphPad Prism (version
5.0). Data are represented asmeans ± SD unless specifically indicated in
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the text. For two-group comparison of continuous data, a two-tailed
Student’s t test was used. For multiple-group comparison, data were
analyzed by one- or two-way ANOVA followed by Bonferroni multiple
comparisons. P ≤ 0.05 was regarded as significant.
SUPPLEMENTARY MATERIALS
www.sciencetranslationalmedicine.org/cgi/content/full/9/406/eaan5954/DC1
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